http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100394075-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 |
| filingDate | 2001-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2003-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100394075-B1 |
| titleOfInvention | Improved bioavailability of itraconazole for oral administration |
| abstract | The present invention relates to oral itraconazole preparations having enhanced bioavailability, and more particularly, by solidifying the itraconazole agent used as an antifungal agent to polyvinylpyrrolidone and an absorption enhancer, and simultaneously crystallizing the crystal of the drug. , Itraconazole is entrapped in polyvinylpyrrolidone and an absorption enhancer, so that even when the dose and the number of times of the drug is less than conventional, it increases the solubility and effective blood concentration in the gastrointestinal tract, thereby dramatically increasing the bioavailability. Accordingly, the present invention relates to oral itraconazole preparations that significantly reduce long-term storage stability due to reduced discomfort and gastrointestinal burden due to overdose of the drug, and in which amorphous itraconazole is not converted into crystalline itraconazole during storage. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017111292-A1 |
| priorityDate | 2000-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.